MeSH D008258 - waldenstrom macroglobulinemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Cyclophosphamide | Neosar |  | 1993-04-29 |  |  |
| Dr Reddys Laboratories | Cyclophosphamide | Cyclophosphamide | 2036-02-15 | 2020-07-30 |  |  |
| Johnson & Johnson | Ibrutinib | Imbruvica |  | 2014-10-21 | $2,964 M | Q2/24-Q1/25 |
| Cipla | Cyclophosphamide | Cyclophosphamide |  | 2019-01-18 |  |  |
| Zydus Therapeutics | Ibrutinib | Ibrutinib |  | 2021-03-31 |  |  |
| Cyclophosphamide | Cyclophosphamide |  | 2023-12-13 |  |  | |
| Alembic Pharmaceuticals | Cyclophosphamide | Cyclophosphamide |  | 2022-11-10 |  |  |
| Amneal Pharmaceuticals | Cyclophosphamide | Cyclophosphamide |  | 2018-05-25 |  |  |
| Bristol Myers Squibb | Thalidomide | Thalidomide BMS (previously Thalidomide Celgene) |  | 2008-04-16 |  |  |
| Thalidomide | Thalomid | 2023-12-09 | 1998-07-16 |  |  | |
| ANI Pharmaceuticals | Cyclophosphamide | Cyclophosphamide |  | 2018-03-19 |  |  |
| Hikma Pharmaceuticals | Cyclophosphamide | Cyclophosphamide |  | 2013-09-16 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
74%73/99
Phase 2
24%25/106
Phase 3
37%11/30
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use